Trial Profile
A Randomized, Placebo-controlled ,Double-blind, Phase IIa Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2022
Price :
$35
*
At a glance
- Drugs Foralumab (Primary) ; Omeprazole
- Indications Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Tiziana Life Sciences
- 10 Sep 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 28 Sep 2017 New trial record